Register Login

GT BIOPHARMA, INC. (GTBP)

SymbolGTBP
NameGT BIOPHARMA, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address9350 WILSHIRE BOULEVARD,SUITE 203, BEVERLY HILLS, California, 90212, United States
Telephone+1 800 304-9888
Fax—
Email—
Websitehttps://www.gtbiopharma.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0000109657
Description

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Additional info from NASDAQ:
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

2026-05-13 18:19

New Form 424B3 - GT Biopharma, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001493152-26-022795 <b>Size:</b> 342 KB

Read more
2026-04-30 17:56

New Form S-1 - GT Biopharma, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001493152-26-020697 <b>Size:</b> 791 KB

Read more
2026-04-07 11:05

(50% Neutral) GT BIOPHARMA, INC. (GTBP) Announces Clinical Development Update

Read more
2026-03-11 11:00

GT Biopharma to Participate in the 38th Annual Roth Conference

Read more
2026-03-11 11:00

GT Biopharma to Participate in the 38th Annual Roth Conference

Read more
2026-03-06 18:01

New Form 10-Q/A - GT Biopharma, Inc. <b>Filed:</b> 2026-03-06 <b>AccNo:</b> 0001493152-26-009127 <b>Size:</b> 8 MB

Read more
2026-03-02 12:05

(99% Neutral) GT BIOPHARMA, INC. (GTBP) Reports Q1 2026 Financial Results

Read more
2026-03-02 12:00

GT Biopharma Reports Full Year 2025 Financial Results

Read more
2026-03-02 09:06

New Form 10-K - GT Biopharma, Inc. <b>Filed:</b> 2026-03-02 <b>AccNo:</b> 0001493152-26-008443 <b>Size:</b> 8 MB

Read more
2026-02-17 12:30

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07541573 GTB-5550 in Advanced Solid Tumors Phase1 Tri-specific Killer Engager Recruiting 2026-04-08 2032-01-01 ClinicalTrials.gov
NCT03214666 GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malig… Phase1 High-risk Myelodysplastic Syndromes Terminated 2020-01-01 2021-09-29 ClinicalTrials.gov
Total clinical trials: 2
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
GTB-3550 TriKE® Phase II Other Phase PHASE1 High-risk Myelodysplastic Syndromes TERMINATED NCT03214666
GTB-3550 TriKE® Phase I Other Phase PHASE1 High-risk Myelodysplastic Syndromes TERMINATED NCT03214666
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-5550 Other Phase PHASE1 Tri-specific Killer Engager RECRUITING NCT07541573
GTB-3550 TriKE® Phase II DRUG Phase PHASE1 High-risk Myelodysplastic Syndromes TERMINATED NCT03214666
GTB-3550 TriKE® Phase I DRUG Phase PHASE1 High-risk Myelodysplastic Syndromes TERMINATED NCT03214666
Total products: 22